Doxorubicin Market Size

Doxorubicin Market size was valued at USD 1.01 billion in 2024 and is set to reach USD 2.24 billion by the end of 2037, expanding at around 6.9% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of doxorubicin is assessed at USD 1.07 billion.

The growth of the market can be attributed to the increasing prevalence of cancer worldwide along with the significant investments in research and development of doxorubicin. The World Health Organization reported that cancer caused nearly 10 million deaths worldwide in 2020. In 2020, breast cancer accounted for 2.26 million cases, lung cancer was 2.21 million, colon and rectal cancer was 1.93 million, prostate cancer was 1.41 million, skin cancer was 1.20 million, and stomach cancer was 1.09 million. As the number of people diagnosed with cancer continues to rise, there is a higher demand for treatments such as doxorubicin, which is an effective form of chemotherapy. Doxorubicin is an anti-cancer drug that works by targeting and destroying cancer cells while leaving healthy cells intact.

In addition to these, factors that are believed to fuel the market growth of doxorubicin include increasing penetration of doxorubicin in emerging countries, the growing number of clinical trials, and increasing investments in oncology research. Moreover, the rise in the number of people suffering from leukemia, a type of cancer affecting the blood and bone marrow is expected to drive market growth. In 2023, the American Cancer Society estimates about 59,610 new cases of leukemia (all types) and 23,710 deaths associated with leukemia will be reported, as well as approximately 20,380 new cases of acute myeloid leukemia (AML) registered. Doxorubicin is used to treat a variety of blood cancers, such as acute myeloid leukemia and Hodgkin's lymphoma. It works by disrupting the production of proteins that cancer cells need to survive.